68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA

Trial Profile

68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 09 May 2017 Status changed from not yet recruiting to recruiting.
    • 13 Apr 2017 Planned number of patients changed from 200 to 60.
    • 13 Apr 2017 Planned End Date changed from 1 Jun 2021 to 1 Aug 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top